White Papers
Bridging the Gap Between Promise and Practicality: Cell and Gene Therapy Advancements, Challenges, and the Path to Commercial Success
In recent years, the field of gene therapy has witnessed remarkable achievements and advancements. These breakthroughs have brought us even closer to unleashing the full potential of gene therapies. Catalent gene therapy experts discuss all aspects of gene therapy commercialization in depth.
View Now
Webinars
Accelerating Your Gene Therapy to Patients: Not All Platforms Are Created Equal
In this fireside chat, George Buchman, Ph.D., Vice President, Pre-Clinical and Process Development, Catalent Cell & Gene Therapy and Thomas VanCott, Ph.D., Chief Scientific Officer, Combined Therapeutics, explore how a complete platform approach to fast-track AAVs can enhance quality and efficiency.
View Now
Webinars
Exploring a One-Stop Integrated Solution for AAV Vector Clinical Production
Learn how the right process, clonal HEK293 cell line, and range of off-the-shelf plasmids, along with qualified analytical methods supports a robust supply chain for the development and manufacture of AAV vectors, and the reduction of timelines to clinical evaluation.
View Now
Webinars
GMP Process for High-Quality iPSC Manufacturing and Development of Improved Differentiation Methodologies
In this webinar, experts will discuss the evolution of protocols associated with induced pluripotent stem cell generation and differentiation.
View Now
Executive Summary
Early Phase Support for Plasmid DNA Supply to Secure Future Manufacturing
Summary: One significant challenge in the manufacturing of cell and gene therapies is the production of high quality plasmid DNA (pDNA). pDNA is a critical raw material for advanced therapeutics including mRNA and viral vector-based cell and gene therapies and vaccines.
View Now
Article
White Papers
Advancing Towards a Universal Platform for iPSC-Based Therapies
Human induced pluripotent stem cells (iPSCs) enable availability of next-generation cell therapies for broader patient population at a faster turnaround time for a variety of disease areas. Catalent iPSC expert Boris Greber discusses the use of iPSCs as starting materials for cellular therapies, including the concept behind a universal platform for iPSC-based therapies.
View Now
White Papers
Integrated Solutions for Advanced Therapies
Drug developers face mounting challenges linked to rapid increases in demand for the complex modalities while also accounting for the need to drive process efficiencies at scale. Working with the right partner, that offers integrated services, can help ease the increasingly common problems with scale, access to high-demand raw material, viral vector production, and quality requirements.
View Now
Video
Catalent Cell & Gene Therapies – Changing the Healthcare Landscape
Summary: Catalent Cell & Gene Therapy experts spoke with American Pharmaceutical Review to discuss how cell and gene therapies are changing the healthcare landscape and what needs to be done to bring these advanced therapies to patients.
View Now
Webinars
Strategic Considerations for Scaling Up the Manufacturing of Cell Therapies
Join us as our panel of experts discuss key manufacturing challenges for early and late-stage gene-enabled cell therapy programs, as well as how to overcome them through effective partnerships.
View Now
Webinars
Overcoming Manufacturing Challenges for Gene-Enabled Cell Therapies
Summary: Join us as our panel of experts discuss key manufacturing challenges for early and late-stage gene-enabled cell therapy programs, as well as how to overcome them through effective partnerships.
View Now